Lingling Li

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Robin L. Jones, J. Blay, K. Götze, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

M. Dimopoulos, S. Jagannath, P. Richardson, 2020, The Lancet.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

M. Dimopoulos, S. Jagannath, S. Lonial, 2019, The New England journal of medicine.

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

J. Shah, M. Dimopoulos, C. Hofmeister, 2020, Leukemia.

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

J. Breeze, M. Dimopoulos, R. Vij, 2021, BMC cancer.

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Lee-Jen Wei, M. Dimopoulos, S. Jagannath, 2020, EJHaem.

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

J. Shah, J. Breeze, M. Dimopoulos, 2020, BMC Cancer.

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

M. Dimopoulos, S. Jagannath, R. Vij, 2018, Blood.

Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).

Lee-Jen Wei, M. Dimopoulos, S. Jagannath, 2019, Journal of Clinical Oncology.

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Blood.

Xiaoyin Jiedu Granules may alleviate psoriasis-like skin diseases in mice by regulating sphingosine 1-phosphate receptor expression and reducing Th17 cells

Hao Zhang, Lingling Li, Guangzhong Zhang, 2023, Heliyon.